Skip to Content

Vivaglobin Approval History

FDA Approved: Yes (First approved January 9, 2006)
Brand name: Vivaglobin
Generic name: immune globulin subcutaneous (human)
Company: ZLB Behring
Treatment for: Primary Immunodeficiency Syndrome

Vivaglobin is a pasteurized, polyvalent human normal immunoglobulin for subcutaneous infusion indicated for the treatment of patients with primary immune deficiency (PID).

Development History and FDA Approval Process for Vivaglobin

Jan  9, 2006Approval Vivaglobin Approved - ZLB Behring - Treatment for Primary Immunodeficiencies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.